Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 42

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 42
---
 in the applicable
prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants represented
by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.

Prior to the exercise of any securities warrants
to purchase preferred stock or common stock, holders of the warrants will not have any of the rights of holders of the common stock or
preferred stock purchasable upon exercise, including in the case of securities warrants for the purchase of common stock or preferred
stock, the right to vote or to receive any payments of dividends on the preferred stock or common stock purchasable upon exercise.

<div align='center'>9

DESCRIPTION OF UNITS</div>

As specified in the applicable prospectus supplement,
we may issue units consisting of shares of common stock, shares of preferred stock or warrants or any combination of such securities.

The applicable prospectus supplement will specify
the following terms of any units in respect of which this prospectus is being delivered:

| ● | the terms of the units and of any of the common stock, preferred stock and warrants comprising the units, including whether and under what circumstances the securities comprising the units may be traded separately; |

| ● | a description of the terms of any unit agreement governing the units; and |

| ● | a description of the provisions for the payment, settlement, transfer or exchange of the units. |

<div align='center'>PLAN OF DISTRIBUTION</div>

We may sell the securities offered through this
prospectus (i) to or through underwriters or dealers, (ii) directly to purchasers, including our affiliates, (iii) through
agents, or (iv) through a combination of any these methods. The securities may be distributed at a fixed price or prices, which may be
changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or negotiated prices. The prospectus
supplement will include the following information:

| ● | the                    
 terms of the offering; |

| ● | the                                  
 names of any underwriters or agents; |

| ● | the                                                        
 name or names of any managing underwriter or underwriters; |

| ● | the                               
 purchase price of the securities; |

| ● | any                                                                                         
 over-allotment options under which underwriters may purchase additional securities from us; |

| ● | the                                          
 net proceeds from the sale of the securities |

| ● | any                           
 delayed delivery arrangements |

| ●